Neuren Pharmaceuticals saw the highest growth of 1.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Neuren Pharmaceuticals’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Neuren Pharmaceuticals has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 50% of filings. The United States(US), Australia(AU), and Israel(IL) patent Office are among the top ten patent offices where Neuren Pharmaceuticals is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for Neuren Pharmaceuticals
Patents related to microbiome and rare diseases lead Neuren Pharmaceuticals's portfolio
Neuren Pharmaceuticals has the highest number of patents in microbiome followed by, rare diseases. For microbiome, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Petrochemicals related patents lead Neuren Pharmaceuticals portfolio followed by cognitive impairment, and apnea
Neuren Pharmaceuticals has highest number of patents in petrochemicals followed by cognitive impairment, apnea, strabismus, and degenerative scoliosis.
For comprehensive analysis of Neuren Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

